MetaCap

Editas Medicine (EDIT) vs Lexeo Therapeutics (LXEO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Editas Medicine (EDIT) has outperformed Lexeo Therapeutics (LXEO) over the past year, losing 32.2% versus a loss of 67.3%. Editas Medicine is the larger company by market cap ($253.1 million vs $245.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EDIT-32.23%LXEO-67.33%
+61%-8%-77%
Nov 21, 20251 yearNov 20, 2026
EDIT-80.26%LXEO-70.55%
+83%-6%-96%
Oct 30, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EDIT versus LXEO key metrics
MetricEDITLXEO
Share price$1.64$2.96
Market cap$253.12M$245.05M
1-day change-4.09%+0.34%
YTD return-20.00%-70.19%
1-year return-32.23%-67.33%
5-year return-94.93%—
EPS (TTM)$-0.54$-1.13
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$40.52M—
Revenue growth (YoY)+25.39%—
Net income (latest FY)$-160.06M$-100.00M
Operating margin-394.89%—
Net margin-395.01%—
52-week high$3.94$10.99
52-week low$1.63$2.55
Distance from 52-week high-58.38%-73.07%
Analyst consensusbuystrong_buy
Avg. price target upside+271.95%+748.31%
Average volume2.63M1.98M
Shares outstanding154.34M82.79M
Employees8768
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EDIT has outperformed LXEO by 35.1 percentage points over the past year.

About Editas Medicine

EDIT stock →

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees

About Lexeo Therapeutics

LXEO stock →

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 68 employees

EDIT vs LXEO FAQ

Which is bigger, Editas Medicine or Lexeo Therapeutics?

Editas Medicine (EDIT) is larger, with a market capitalization of $253.12M compared with $245.05M for Lexeo Therapeutics (LXEO).

Which stock has performed better over the past year, EDIT or LXEO?

EDIT returned -32.23% over the past 12 months, compared with -67.33% for LXEO (price return, excluding dividends). Past performance does not predict future results.

Are Editas Medicine and Lexeo Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons